T-1501 / Taivex Therapeutics Corporation - LARVOL DELTA

Preparation of Lactobacillus paracei TK1501 postbiotic and its inhibitory effect against Helicobacter pylori infection in mice (PubMed, Nan Fang Yi Ke Da Xue Xue Bao) - "L. paracasei TK1501 postbiotic has strong inhibitory effects on Hp and Staphylococcus aureus but not on normal intestinal flora in mice."

Journal • Preclinical • Infectious Disease • IL1B • TNFA

Clinical value of foot thermometry in patients with acute limb ischemia. (PubMed, Vascular) - "Current study demonstrated that patients with immediately threatening ALI have significantly lower foot temperature than those with viable and marginally threatened limbs. Severe foot poikilothermy at admission is associated with poor outcomes of revascularization, mostly with limb loss."

Journal • Cardiovascular • Pain

The Influence of Thermoplastic Composite Recycling on the Additive Manufacturing Process and In-Use Phase as Candidate Materials for Wearable Devices Applications. (PubMed, Polymers (Basel)) - "Tritan Copolyester TX1501 with 7.3% chopped CFs (cCFs) and Polyamide 12 (PA12) with 8.6%cCFs and 7.5% iron Magnetic Nanoparticles (MNPs)-FeO were used in the discrete ascending cycles of recycling, focusing on the surface quality performance optimization of the printed parts...The results indicate that after applying certain adjustments to the main printing parameter values, the examined recycled reinforced materials are still effectively 3D printed even after multiple cycles of recycling. A morphology examination using scanning electron microscope (SEM) revealed surface alterations, while a cytotoxicity assessment revealed the adverse effects of both materials in the form of cell viability and the release of proinflammatory cytokines in the cell culture medium."

Journal

Taiwei Biotech successfully developed two new anti-cancer drugs to apply for phase II clinical trials by the end of this year [Google translation] (money.udn.com) - "Zhao Yusheng, general manager of Taiwei Biotechnology, said that the company currently has four First-in-Class/ Best-in-Class Targeted anti-cancer drugs, including T-1101 and T-1201, two new anti-cancer drugs with different mechanisms of action, are expected to be put forward for Phase II clinical trials by the end of this year....T-1501 is undergoing preclinical toxicology experiments. It is expected to apply for IND in Taiwan and the United States early next year and carry out the first phase of clinical trials."

IND • New P1 trial • New P2 trial • Oncology • Solid Tumor